Jun 17, 2014
Selecta Biosciences Enters Into Exclusive License Agreement with...
Selecta Biosciences Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced it has entered into an exclusive license with 3SBio for pegsiticase , a pegylated recombinant uricase from candida utilis .
China Biotech In Review: Fundings For China-Affiliated Drug Companies
Shenogen Pharma of Beijing raised $20 million in a series C funding, which the company will use to support a Phase II trial of its lead drug candidate, icaritin, a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer.